Serum CCL2 and serum TNF-α – Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma

2011 ◽  
Vol 47 (3) ◽  
pp. 339-346 ◽  
Author(s):  
Xing Lu ◽  
Chao-Nan Qian ◽  
Yong-Gao Mu ◽  
Ning-Wei Li ◽  
Su Li ◽  
...  
Keyword(s):  
Overall Survival ◽  
Nasopharyngeal Carcinoma ◽  
Distant Metastasis ◽  
Post Treatment ◽  
Bone Invasion ◽  
Poor Overall Survival ◽  
Tnf Α ◽  
New Biomarkers

CORRELATION OF TNF-Α EXPRESSION TO CLINICAL STADIUM IN NASOPHARYNGEAL CARCINOMA

2020 ◽  
Vol 2 (01) ◽  
pp. 04-06
Author(s):  
Riko Susilo ◽  
Farhat ◽  
Rizalina A Asnir ◽  
Ashri Yudhistira ◽  
Elvita Rahmi Daulay ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
General Hospital ◽  
Distant Metastasis ◽  
Clinical Stage ◽  
Stage Iv ◽  
P Value ◽  
Age Group ◽  
Bone Invasion ◽  
Tnf Α ◽  
Post Therapy

Introduction: Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Indonesia with over 13.000 new cases reported yearly, especially in the male. The TNF-α serum is reported as a new biomarker to predict bone invasion, post-therapy distant metastasis, and poor life sustainability in NPC. Objective: To identify the expression of TNF-α in regards to the clinical stage of NPC. Material and methods: This is an analytic study with 126 NPC samples of patients in Haji Adam Malik General Hospital. Results: NPC mostly found in age group 41-60 years (57.1%), male (71.4%),non-keratinizing SCC (79.4%), and stage IV group (54.8%). In immunohistochemistry evaluation, most of TNF-α overexpressed in non-keratinizing SCC(68.0%), T3-T4 (50.8%), N2-N3 (62.7%) and clinical stage III-IV (69.9%). Spearman's test for categorical correlation yield a p-value of <0,001. Conclusion: There is a significant correlation between TNF-α expression and the stage of NPC.

scholarly journals Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China: 5-Year Outcomes

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Lei Du ◽  
Xin-Xin Zhang ◽  
Lin Ma ◽  
Lin-Chun Feng ◽  
Fang Li ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Overall Survival ◽  
Nasopharyngeal Carcinoma ◽  
Distant Metastasis ◽  
Helical Tomotherapy ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Distant Metastasis Free Survival

Background.To evaluate the outcomes of nasopharyngeal carcinoma (NPC) patients treated with helical tomotherapy (HT).Methods.Between September 2007 and August 2012, 190 newly diagnosed NPC patients were treated with HT. Thirty-one patients were treated with radiation therapy as single modality, 129 with additional cisplatin-based chemotherapy with or without anti-EGFR monoclonal antibody therapy, and 30 with concurrent anti-EGFR monoclonal antibody therapy.Results.Acute radiation related side effects were mainly grade 1 or 2. Grade 3 and greater toxicities were rarely noted. The median followup was 32 (3–38) months. The local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were 96.1%, 98.2%, 92.0%, and 86.3%, respectively, at 3 years. Cox multivariate regression analysis showed that age and T stage were independent predictors for 3-year OS.Conclusions.Helical tomotherapy for NPC patients achieved excellent 3-year locoregional control, distant metastasis-free survival, and overall survival, with relatively minor acute and late toxicities. Age and T stage were the main prognosis factors.

scholarly journals Chemotherapy Negates the Effect of SDF1 mRNA to Distant Metastasis and Poor Overall Survival in Breast Cancer Patients

2021 ◽  
Vol 22 (3) ◽  
pp. 757-766
Author(s):  
Kristanto Yarso ◽  
Monica Bellynda ◽  
Akhmad Azmiardi ◽  
Brian Wasita ◽  
Didik Heriyanto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Breast Cancer Patients ◽  
Poor Overall Survival

scholarly journals Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (19) ◽  
pp. 27458-27467 ◽  
Author(s):  
Jin Wang ◽  
Li Li ◽  
Bai-qiang Dong ◽  
Yu-jin Xu ◽  
Yuan-da Zheng ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Distant Metastasis ◽  
Lactic Dehydrogenase ◽  
Post Treatment ◽  
Serum Lactic Dehydrogenase ◽  
Predictive Indicator

Association of loss of nuclear BAP1 expression with prognosis in oral mucosal melanoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21021-e21021
Author(s):  
Wei Guo
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Distant Metastasis ◽  
Immunohistochemical Staining ◽  
Genetic Alterations ◽  
Mucosal Melanoma ◽  
Independent Prognostic Factor ◽  
Missense Mutations ◽  
Poor Overall Survival ◽  
Oral Mucosal Melanoma

e21021 Background: The prognostic factors of oral mucosal melanoma (OMM),a rare and aggressive neoplasm, remain to be determined. BAP1 is a tumor suppressor that has been associated with the outcome of melanomas and other malignancies. In this study, we investigated the genetic alterations in BAP1 and the prognostic potential of BAP1 protein expression in oral mucosal melanoma. Methods: DNA sequence analysis of BAP1 from 12 OMM patient samples revealed missense mutations in the tissues from four patients. Results: Based on immunohistochemical staining, loss of nuclear BAP1 expression was associated with poor overall survival (P < 0.001, Log-rank = 21.308) and distant metastasis (P = 0.034, OR = 0.320). Multivariate analysis showed BAP1 to be an independent prognostic factor (P = 0.027, HR = 0.479). Conclusions: It thus appears that loss of nuclear BAP1 expression is an independent prognostic factor of poor overall survival and associated with distant metastasis in OMM.

scholarly journals Diffusion-weighted MRI for predicting treatment response in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Min Kyoung Lee ◽  
Yangsean Choi ◽  
So-Lyung Jung
Keyword(s):  
Overall Survival ◽  
Nasopharyngeal Carcinoma ◽  
Treatment Response ◽  
Distant Metastasis ◽  
Meta Analysis ◽  
Local Relapse ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Distant Metastasis Free Survival ◽  
Hazard Ratios

AbstractEarly prediction of treatment response in nasopharyngeal carcinoma is clinically relevant for optimizing treatment strategies. This meta-analysis was performed to evaluate whether apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) can predict treatment response of patients with nasopharyngeal carcinoma. A systematic search of PubMed-MEDLINE and Embase was performed to identify relevant original articles until July 22, 2021. We included studies which performed DWI for predicting locoregional treatment response in nasopharyngeal carcinoma treated with neoadjuvant chemotherapy, definitive chemoradiation, or radiation therapy. Hazard ratios were meta-analytically pooled using a random-effects model for the pooled estimates of overall survival, local relapse-free survival, distant metastasis-free survival and their 95% CIs. ADC showed a pooled sensitivity of 87% (95% CI 72–94%) and specificity of 70% (95% CI 56–80%) for predicting treatment response. Significant between-study heterogeneity was observed for both pooled sensitivity (I2 = 68.5%) and specificity (I2 = 92.2%) (P < 0.01). The pooled hazard ratios of low pretreatment ADC for assessing overall survival, local relapse-free survival, and distant metastasis-free survival were 1.42 (95% CI 1.09–1.85), 2.31 (95% CI 1.42–3.74), and 1.35 (95% CI 1.05–1.74), respectively. In patients with nasopharyngeal carcinoma, pretreatment ADC demonstrated good predictive performance for treatment response.

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial

2022 ◽  
Author(s):  
Xiao-Yun Li ◽  
Dong-Hua Luo ◽  
Ling Guo ◽  
Hao-Yuan Mo ◽  
Rui Sun ◽  
...  
Keyword(s):  
Overall Survival ◽  
Nasopharyngeal Carcinoma ◽  
Distant Metastasis ◽  
Epstein Barr Virus ◽  
Low Risk ◽  
Free Survival ◽  
Barr Virus ◽  
Epstein Barr ◽  
Grade 3 ◽  
Cycle Group

PURPOSE Cumulative doses of 200 mg/m2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority of a two-cycle 100 mg/m2 concurrent DDP regimen over three-cycle in patients with low-risk LA-NPC with pretreatment Epstein-Barr virus DNA levels < 4,000 copies/mL. PATIENTS AND METHODS Eligible patients were randomly assigned 1:1 to receive two cycles or three cycles concurrent DDP-based chemoradiotherapy. The primary end point was 3-year progression-free survival (PFS). The secondary end points included overall survival, distant metastasis-free survival, locoregional relapse-free survival, etc. RESULTS Between September 2016 and October 2018, 332 patients were enrolled, with 166 in each arm. After a median follow-up of 37.7 months, the estimated 3-year PFS rates were 88.0% in the two-cycle group and 90.4% in the three-cycle group, with a difference of 2.4% (95% CI, –4.3 to 9.1, Pnoninferiority = .014). No differences were observed between groups in terms of PFS, overall survival, and the cumulative incidences of locoregional relapse and distant metastasis. Patients in the three-cycle group developed significantly more grade 3-4 mucositis (41 [24.8%] v 25 [15.1%]), hyponatremia (26 [15.8%] v 14 [8.4%]), and dermatitis (9 [5.5%] v 2 [1.2%]). The overall all-grade and grade 3-4 toxicity burdens were heavier in three-cycle group (T-scores, 12.33 v 10.57, P < .001 for all grades; 1.76 v 1.44, P = .05 for grade 3-4). Patients in the three-cycle group also showed more all-grade hearing impairment, dry mouth and skin fibrosis, and impaired long-term quality of life. CONCLUSION Intensity-modulated radiotherapy plus two cycles of concurrent 100 mg/m2 DDP could be an alternative treatment option for patients with low-risk LA-NPC.

COX-2 expression and mesenchymal-transition status on circulating tumor cells to predict survival in patients with nasopharyngeal carcinoma: A prospective analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6042-6042
Author(s):  
Yongjiang Li ◽  
Xiaoqi Xie ◽  
Hong Zhang ◽  
Chen Lv ◽  
Dongyan Miao ◽  
...  
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Nasopharyngeal Carcinoma ◽  
Tumor Cells ◽  
Prognostic Indicator ◽  
Post Treatment ◽  
Mesenchymal Transition ◽  
Tumor Relapse ◽  
Cox 2 ◽  
Expression Status

6042 Background: The prognostic significance of circulating tumor cells (CTCs) in head and neck cancer is still under active investigation. It remains unclear whether just CTC count alone is sufficient to predict outcomes or whether the functional status of the CTCs is also needed. We investigated the clinical significance of determining epithelial-to-mesenchymal transition status and geno-/pheno-typic biomarkers of aggressiveness of CTCs in predicting outcomes in nasopharyngeal carcinoma (NPC). Methods: The prospective study enrolled 131 patients with NPC. CTCs were isolated at baseline and at the end of concurrent chemoradiotherapy using the CanPatrol system. Subsequently, the epithelial-mesenchymal transition (EMT) biomarkers and cyclooxygenase-2 (COX-2) expression status of the CTCs were identified by RNA-in situ hybridization (ISH) method. Results: COX-2 expression was found in 87/131 (66.4%) patients at baseline and 53/115 (46.1%) patients post-treatment. Independent of initial COX-2 expression status, the patients with post-treatment COX-2 expression on CTCs had significantly poorer treatment response (P = 0.011), and higher risk of tumor relapse (P = 0.026) and metastasis (P = 0.007). Similarly, post-treatment mesenchymal transition was also associated with higher risk of tumor relapse and metastasis. In multivariate analysis, post-treatment COX-2 expression on CTCs remained an independent prognostic indicator of poorer overall survival (HR 2.41, 95% CI 1.12-5.19; P = 0.024). Post-treatment COX-2 expression and mesenchymal transition in CTCs was the strongest prognostic indicator of overall survival on multivariate analysis (HR 2.73, 95% CI 1.28-5.83; P = 0.009). Conclusions: Post-treatment COX-2 expression on CTCs, especially on the mesenchymal subtype, is a novel and promising prognostic indicator for NPC patients treated with chemoradiation therapy. Future studies are needed to validate our findings and further clarify the value of integrating the indicators with current clinical strategies in improving survival of NPC patients.

Sign in / Sign up

Export Citation Format

Share Document